Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate. - Wikidata - awgldk - TriplyDB

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

http://www.wikidata.org/entity/Q37370563

about

Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Novel targeted therapy for neuroblastoma: silencing the MXD3 gene using siRNA.

P2860

Q39381251-7EBA12B6-62AA-4981-9A06-A6FE8EFD1A6A Q46197587-C7EA0CBC-FA35-4436-81B3-B774A41F63BA

P2860

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

http://www.wikidata.org/entity/Q37370563

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel Targeted Therapy for Pre ...... nse Oligonucleotide Conjugate.

@en

Novel Targeted Therapy for Pre ...... nse Oligonucleotide Conjugate.

@nl

type

label

Novel Targeted Therapy for Pre ...... nse Oligonucleotide Conjugate.

@en

Novel Targeted Therapy for Pre ...... nse Oligonucleotide Conjugate.

@nl

prefLabel

Novel Targeted Therapy for Pre ...... nse Oligonucleotide Conjugate.

@en

Novel Targeted Therapy for Pre ...... nse Oligonucleotide Conjugate.

@nl

P1433

Q37370563-8C0EB525-B3F6-49A8-ABC2-046439863487

P1476

Q37370563-A3D2D494-F4AB-4707-B267-387DA505CAF3

P2093

Q37370563-1C47A251-B17D-4A3E-B42E-64EE812233F9

Q37370563-328D83A2-D71B-40B2-9BBF-FF8D0909A914

Q37370563-4058B128-258A-47BB-8229-B2148C1FE78E

Q37370563-710E2DED-81D8-4DFD-9C0C-DB08ECEEDDF7

Q37370563-7F0A5169-4D99-48F0-8842-2CEB44187CCA

Q37370563-87CC875E-E47D-447D-A784-3008E4CB68F5

Q37370563-891EF39C-6BC3-47A4-A42B-34F1426331D1

Q37370563-B8D414C7-1040-43EE-B86B-25729F21A2A7

Q37370563-E0EA168D-E46C-43F7-87D0-D97848325DE9

Q37370563-E6675665-C4B8-47BA-9170-EAC53C9EEF9D

P2860

Q37370563-06E1D32E-6D1A-4A70-8BC2-F3C70D5D2F7C

Q37370563-0D146662-25F9-469D-8FEA-948BD5436224

Q37370563-1CF4AFE7-B45F-42B7-A44F-2A542D9169F8

Q37370563-22B46A7F-5257-4427-B44B-3DA70EBAD5C3

Q37370563-275E7319-B8EE-44C2-9FC5-C0C07DD98F5A

Q37370563-2BDDE933-CEEE-4D7E-8AE6-12EA9D0482C2

Q37370563-3E2CC659-5FF3-453F-8017-4ABE37001A18

Q37370563-411ECC31-A466-4871-A3EE-4D8AD36A72C0

Q37370563-41DF7DB7-D070-459C-BDD0-4BA73F12E289

Q37370563-45A97F17-EF23-42CF-B070-84C8B3B62E36

P2888

Q37370563-AD79724C-CB09-4F78-A6DA-52A1F41612DA

P304

Q37370563-C4EFC3BA-5725-4786-97C6-877E5B961769

P31

Q37370563-19CF8567-BFEA-4D84-AA04-7D9EF8C6896E

P356

Q37370563-A9E3B6DF-BBE9-4130-8960-B56CEEBBDED3

P407

Q37370563-00100077-8061-4822-B978-D17C70BE329A

P478

Q37370563-72621C98-2908-4FFD-9FBC-F3EB1BBB77FC

P50

Q37370563-C7D1D683-385B-4428-B9E6-B38BFE21935E

P577

Q37370563-6517507E-F74D-4B2D-A187-0225909F24B0

P6179

Q37370563-7F95EEFE-2DA3-4829-B731-68DF5673890A

P698

Q37370563-60F88561-9CB2-44BD-8A54-46D574894EC1

P932

Q37370563-84EB7B90-A1F5-45A8-BC10-BCDDD08E6A69

P356

MOLMED.2015.00210

P1433

Molecular Medicine

P1476

Novel Targeted Therapy for Pre ...... ense Oligonucleotide Conjugate

@en

P2093

Cathy Chen

http://www.w3.org/2001/XMLSchema#string

Connie Duong

http://www.w3.org/2001/XMLSchema#string

Jong Chung

http://www.w3.org/2001/XMLSchema#string

Joseph M Tuscano

http://www.w3.org/2001/XMLSchema#string

Laurel Beckett

http://www.w3.org/2001/XMLSchema#string

Michael Oestergaard

http://www.w3.org/2001/XMLSchema#string

Nitin Nitin

http://www.w3.org/2001/XMLSchema#string

Noriko Satake

http://www.w3.org/2001/XMLSchema#string

Punit P Seth

http://www.w3.org/2001/XMLSchema#string

Rachael Peralta

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance

The Myc/Max/Mad network and the transcriptional control of cell behavior

A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems

Mylotarg: antibody-targeted chemotherapy comes of age.

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Evidence that myosin activity opposes microtubule-based axonal transport of mitochondria.

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

P2888

molmed.2015.00210

P304

632-642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/MOLMED.2015.00210

http://www.w3.org/2001/XMLSchema#string

P407

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1068965799

http://www.w3.org/2001/XMLSchema#string

P698

27455414

http://www.w3.org/2001/XMLSchema#string

P932

5082301

http://www.w3.org/2001/XMLSchema#string